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The effects of repeated reserpine on the in vivo regional brain distribution of [ISF]GBR 13119 (1-[(4-[l~F]fluoro - 
phenyl)(phenyl)methoxy)ethyl]-4-(3-phenylpropyl)piperazine), a dopamine uptake inhibitor, have been examined. Repeated 
parenteral administration of reserpine (2 mg/kg i.p., once daily for three days) causes a decrease of the in vivo specific binding 
of [~SF]GBR 13119 in mouse striatum, consistent with a down-regulation of available uptake sites in response to dopamine 
depletion. These results indicate that modification of endogenous dopamine concentrations, either due to pathological 
disturbance or pharmacological interventions, may affect in vivo studies of the dopamine uptake system using radioligands of the 
1,4-dialk(en)ylpiperazine class, and complicate the intepretation of in vivo human studies of these radioligands using positron 
emission tomography. 
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1. Introduction 
Dopamine  (DA) reuptake by presynaptic neurons is 
an important  component  of the termination of neuro- 
transmission, and serves a dual function as a means for 
recovery and conservation of synthesized DA. The 
specific, membrane-bound dopamine uptake carrier has 
been proposed by ourselves and others as a candidate 
for new radioligand development for in vivo imaging of 
dopaminergic neurons. These efforts have resulted in 
successful imaging of the DA uptake site in living 
human brain using [11C]nomifensine (Aquilonius et al., 
1987), [18F]GBR 12909 (Koeppe et al., 1990), and 
[llC]cocain e (Fowler et al., 19891. 
The interpretation of changes in the in vivo distribu- 
tion of such radiotracers is not straightforward. To 
date, decreases in radiotracer uptake due to stereotac- 
tic lesioning (Ciliax et al., 1990) or neurotoxic insult 
(Leenders et al., 1988; Kilbourn et al., 1991a) in ani- 
mals, or disease in humans (Salmon et al., 1990), has 
been attributed to the loss of dopaminergic neurons~ 
Such conclusions would be supported by experimental  
data which demonstrates  that in vivo radioligand bind- 
ing is not affected by levels of endogenous neurotrans- 
mitter. Previous investigations have provided contra- 
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dictory results on the effects of DA depletion or en- 
hancement  on the binding of radioligands for the DA 
uptake site (Janowsky et al., 1985; Vaugeois et al., 
1990; Maurice et al., 1991). These different results 
could be due to methodological issues, or the use of 
structurally different radioligands. We have examined 
here the effects of repeated treatments with reserpine, 
a vesicular monoamine uptake blocker which depletes 
tissue DA, on the in vivo binding of [I~F]GBR 13119 
(1-((4-[ 18F]fluorophenyl)(phenyl)methoxy)ethyl]_4(_3_ 
phenylpropyi)piperazine),  a DA uptake inhibitor of the 
1,4-dialk(en)ylpiperazine class. 
2. Materials and methods 
2.1. Animals and treatments 
All studies were done in female CD-1 mice, 20-25 g 
(Charles River). Six t reated animals and an equal num- 
ber  of untreated control animals were used. Reserpine 
t reatment  regimen was 2 mg /kg ,  i.p., once daily for 
three days. Animals were used for in vivo radiotracer 
experiments 24 h after the last reserpine injection. 
2.2. Radioligands 
No-carrier-added,  high specific activity ( >  1000 
C i / m m o l )  [18F]GBR 13119 was prepared as previously 
described (Kilbourn and Haka,  1989). 
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2.3. In t,il'o radiotracer studies 
Mice were anaesthetized (diethyl ether) and injected 
with 2-10 p.Ci of [~SF]GBR 13119 (mass dose 17 to 86 
ng/kg),  then allowed to recover. After 1 h, the animals 
were killed by decapitation and the brain rapidly ex- 
cised and dissected into striatum, whole cortex, and 
whole cerebellum. A blood sample was also obtained. 
The tissue samples were weighed and then counted for 
fluorine-18 using an automated y-counter. These data 
were used to calculate the % injected dose /g  ( % I D / g )  
for each brain region and for blood. 
2.4. Statistical analysis 
Statistical analysis was conducted using an unpaired 
Student's t-test. 
3. Results 
Repeated reserpine (2 mg /kg  i.p., once daily for 
three days) significantly decreased the concentration of 
[JSF]GBR 13119 in the mouse striatum, as shown in 
table 1. Specific binding, expressed as either the differ- 
ence between striatum and cerebellum or as the stria- 
t um/ce rebe l lum ratio, were also significantly reduced 
by > 39%. Tissue concentrations of the radiotracer 
was significantly increased in cortex, cerebellum and 
blood, as compared to controls, but there was no 
specific binding of [18F]GBR 13119 in the cortex of 
either controls or reserpine-treated animals. For this 
study, radioligand accumulation in cerebellum was as- 
signed as due only to non-specific binding, as there are 
no DA uptake carriers in cerebellum and the uptake of 
[18F]GBR 13119 in this brain region is unaffected by 
pharmacological pretreatment with the DA uptake in- 
hibitors mazindol,  nomifensine of GBR 12909 
(Kilbourn, 1988). 
T A B L E  1 
Effects of repeated reserpine (2 m g / k g  i.p., once daily for three 
days, last injection 24 h prior  to injection of radiotracer)  on the 
regional mouse  brain accumulat ion of  [18F]GBR 13119. Radiotracer  
was injected i.v. and animals killed at 1 h after injection. Values are 
m e a n s + S . D .  (n = 6). Number s  in paren theses  are the differences 
between control and reserpine- t reated animals. 
Tissue Control  Reserpine  
(% injected d o s e / g )  (% injected d o s e / g )  
Str ia tum 2.33 + 0.63 
Cortex 0.64 -+ 0.13 
Cerebel lum 0.58 -+ 0.13 
Blood 1.03 + 0.11 
S t r i a t u m -  cerebel lum 1.66 +_ 0.6 
S t r i a tum/ce rebe l l um 3.66+0.71 
1.77 _+ 0.19 ( - 25%) a 
0.91 +0.14 ( + 4 2 % )  ~' 
0.75 -+ 0.16 ( + 29%) a 
1.55 -+ 0.27 ( + 50%) a 
1.05 -+ 0.39 ( - 58%) a 
2.25 -+ 0.39 ( - 39%) ~ 
a p < 0.05 vs. control. 
4. Discussion 
Radiolabeled DA uptake inhibitors have been pro- 
posed as in vivo markers of neuronal integrity, with an 
anticipated use in monitoring the progression of degen- 
erative processes such as Parkinson's disease (Aqui- 
Ionius et al., 1987; Koeppe et al., 1990; Salmon et al., 
1990). To function as a marker of neurons, radioligand 
binding should not be influenced by transient alter- 
ations in endogenous DA levels. Acute reserpine (5 
mg/kg,  4 h prior) or L-DOPA (200 mg/kg  i.p.+ 50 
m g /k g  benzeraside, 2 h prior) have been reported not 
to affect the specific striatal in vivo accumulation of 
[3H]GBR 12783 in mouse brain (Vaugeois et al., 1990), 
but the same treatments have been reported to in- 
crease (reserpine treatment) and decrease (L-DOPA 
treatment) the specific in vivo binding of [3H]BTCP 
([3H]N-[1-(2-benzo(b)thiophenyl)-cyclohexyl]piper i -  
dine) (Maurice et al., 1991). These studies cannot be 
directly compared, however, as they use different radi- 
oligands and different methods of determining in vivo 
specific binding. 
In our hands, repeated reserpine treatment (table 1) 
decreased the in vivo specific striatal binding, defined 
as striatum minus cerebellum, of [ISF]GBR 13119 by 
nearly 60%. This reduction in specific striatal binding 
of [ISF]GBR 13119 provides support for down-regu- 
lation of available DA uptake sites upon DA depletion, 
which would be consistent with an adaptive process to 
reduce the uptake capacity and maintain synaptic lev- 
els of DA (Zigmond et al., 1990), and is similar to the 
reported 59% reduction in norepinephrine reuptake 
sites in rat brain cortex after repeated reserpine pre- 
treatment (Lee et al., 1983). The observed reduction in 
[~SF]GBR 13119 binding is also similar in magnitude 
but opposite in direction to the change in striatal 
binding of [3H]raclopride in reserpine-treated rats. 
In the reserpinized animals there was also observed 
an increase of radiotracer uptake in non-target tissues 
such as cerebellum (+  29%), which most likely reflects 
an increased delivery of radioligand to all brain tissues 
due either to the elevated blood levels or increased 
blood-brain barrier permeability for the radioligand. 
Increased radioligand concentrations in cerebellum 
have been previously noted in the uptake of [3H]GBR 
12783 (+4 8 %;  Vaugeois et al., 1990) and [3H]BTCP 
(+90%;  Maurice et al., 1991), and also in unrelated 
studies of in vivo uptake of [3H]raclopride (Ross and 
Jackson, 1989). These studies employing reserpine pre- 
treatment demonstrate the importance of considering 
radiotracer delivery when interpreting apparent in- 
creases in radiotracer accumulation after pharmacolog- 
ical interventions. Increases in the absolute amount of 
specifically bound radioligand, as observed for 
[3H]BTCP, can be attributed to increased radioligand 
availability for binding to the DA uptake site, rather 
than an increase in the number of available sites. On 
the other hand a decrease in radiotracer binding, as 
observed for [~SF]GBR 13119, with a concomitant in- 
crease in radiotracer delivery cannot be so explained, 
and the observed decrease in specific binding may in 
fact be an underestimation of the true 'loss' of avail- 
able binding sites. In the extreme case, increased deliv- 
ery may obscure smaller 'losses' of apparent binding 
sites, resulting in no apparent effect of drug treatment. 
The hypothesis that the numbers of dopamine up- 
take carriers may be regulated by the chronic concen- 
tration of DA would be consistent with the concept of 
synaptic homeostasis (Zigmond et al, 1990) in normal 
animals. In this study, we have assigned a reduction in 
[~F]GBR 13119 binding to a loss of DA uptake sites, 
although a change in the K D for the radioligand might 
also reduce the in vivo binding; however, there is no 
precedence for changes of in vivo K D values for this 
class of radioligands. Separation of K D and B ..... was 
not attempted in this study, as for imaging purposes 
these variables are often lumped together into a com- 
bined term (such as binding potential (B .... /KD) ,  vol- 
ume of distribution, or related terms). The possible 
regulation of 'available' DA uptake sites by levels of 
endogenous DA would have important ramifications 
for the interpretation of in vivo imaging studies of this 
system, as a lower radiotracer accumulation may in fact 
reflect less available DA uptake sites per surviving 
neurons rather than a loss of neurons. An interesting 
question remains as to the mechanism for this appar- 
ent loss of DA uptake sites, as chronic reserpine did 
not reduce the number of [3H]threo-(_+)-methyl- 
phenidate binding sites in rat brain determined using 
in vitro assays of rat striatal membranes (Janowsky et 
al., 1985). The possibility of intact but non-functional 
DA transporters would have further impact on both 
the interpretation of in vivo imaging studies, as well as 
new therapeutic regimens for treatment of Parkinson's 
disease. 
A second important consideration for in vivo studies 
will be the possible competition of endogenous DA for 
radioligand binding. In normal animals the in vivo 
binding of [3H]GBR 12783 does not seem to be af- 
fected by raising DA levels through L-DOPA treat- 
ment (Vaugeois et al., 1990). In preliminary studies, we 
have found that repeated pargylline treatment (10 
mg / kg  i.p., once daily for 14 days) at a dose which 
should inhibit > 80% of monoamine oxidase B (Zsilla 
et al., 1983) does not alter specific [~SF]GBR 13119 
binding (Kilbourn et al., 1991b). Together  these studies 
suggest that this class of high affinity radioligands is 
not affected by competition from endogenous DA, in 
contrast to the apparent reduction of in vivo binding of 
[3H]BTCP after L-DOPA treatment (Maurice et al., 
1991). Only a direct comparison of [lSF]GBR 13119 (or 
[3H]GBR 12783) and [3H]BTCP in reserpinized ani- 
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mals would answer the question of whether different 
kinetics of association and dissociation, or different 
methods for tissue analysis, are responsible for the 
divergent results. That endogenous DA might have 
different effects on these structurally unrelated drugs 
might not be a surprise, as similar results have been 
observed in studies of the effects of reserpine or am- 
phetamine on DA O 2 radioligands in vivo. Spiperone 
and structurally related butyrophenone neuroleptics 
have been reported to show no change (De Jesus et al., 
1986; Seeman et al., 1989; Young et al., 1991) or 
decreased (Bischoff et al., 1991; Chugani et al., 1988) 
binding in reserpinized animals, yet also exhibit de- 
creased in vivo binding after pretreatment with the DA 
releaser amphetamine (Dewey et al., 1991). Conversly, 
benzamide neuroleptics such as raclopride showed an 
increased specific binding in the striatum (higher stria- 
turn/cerebel lum ratios) after pretreatment with reser- 
pine (Seeman et al., 1989; Young et al., 1991), and 
decreased binding after amphetamine pretreatment 
(Ross and Jackson, 1989). 
In summary, we have demonstrated that the in vivo 
specific binding of the radioligand [~SF]GBR 13119 to 
the DA uptake carrier can be altered by depletion of 
endogenous DA. These results suggest that in vivo 
studies of the DA uptake system in neurodegenerative 
diseases, including human brain imaging of the distri- 
bution of carbon- l l  or fluorine-18 labeled radioligands 
using positron emission tomography, may not simply 
reflect loss of dopaminergic terminals but may also 
provide additional information on the functional status 
of the uptake system in the diseased state. 
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